BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder Aug 15, 2023
BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder Jul 18, 2023
BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting Mar 7, 2023
BioCorRx Attended 4th Annual NIH HEAL Initiative Investigator Meeting; Shares Update on BICX104 Data Feb 23, 2023
BioCorRx Appoints Pharmaceutical & Finance Veteran Harsha Murthy to the Board of Directors Jan 24, 2023
